Concepedia

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with <i>in vitro</i> antitumor activity towards non-small lung cancer

Esraa A. Abdelsalam, Amer Ali Abd El‐Hafeez, Wagdy M. Eldehna, Mahmoud A. El Hassab, Hala Mohamed M. Marzouk, Mahmoud M. Elaasser, Nageh A. Abou Taleb, Kamilia M. Amin, Hatem A. Abdel‐Aziz, Pradipta Ghosh,

Journal of Enzyme Inhibition and Medicinal Chemistry · 2022 · 76 citations · 44 references

DOIFull text

Open access

Concepts

Abstract

induce G2/M cell cycle arrest and apoptosis and inhibit migration in A549 cancerous cells.

References

44

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi et al. · New England Journal of Medicine · 2010 · 5.6K citations

, , +13

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

, , +12

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

, , +16

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Cai‐Hong Yun, Kristen E. Mengwasser, Angela V. Toms et al. · Proceedings of the National Academy of Sciences · 2008 · 2.1K citations · Full text

, , +14

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text

, , +11